Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nektar Therapeutics (NKTR)
NASDAQ:NKTR
Nektar Therapeutics (NKTR) Stock Forecast & Price Target
1,166 Followers
See the Price Targets and Ratings of:
NKTR Analyst Ratings
Hold
0 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NKTR Stock 12 Month Forecast
Average Price Target
$1.00
▲(7.04% Upside)
| Highest Price Target$1.00 | Average Price Target$1.00 | Lowest Price Target$1.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Oppenheimer
―
Hold
―
Initiated
12/11/23
Oppenheimer Initiates a Hold Rating on Nektar Therapeutics (NKTR)
J.P. Morgan
―
Sell
―
Initiated
11/20/23
Nektar reinstated with an Underweight at JPMorganNektar reinstated with an Underweight at JPMorgan
TD Cowen
―
Buy
―
Upgraded
11/09/23
Positive Report for Nektar Therapeutics (NKTR) from TD Cowen
Mizuho Securities
$5.00
Hold
435.22%
Upside
Assigned
11/08/23
Nektar price target lowered to $5 from $6 at MizuhoNektar price target lowered to $5 from $6 at Mizuho
Leerink Partners
$1.50
Hold
60.57%
Upside
Reiterated
09/15/23
We are incrementally more positive on rezpeg’s (rezpegaldesleukin, Treg-biased PEGylated IL-2) prospects in atopic dermatitis (AtD) following Nektar’s (NKTR, MP) presentation of updated Ph 1b data and development plans. We are encouraged that rezpeg demonstrated consistent clinical benefit and dose response across multiple efficacy endpoints, including EASI, but also other outcomes including pruritus (itch) numeric rating scale (NRS) where Nektar teased out rezpeg benefit by excluding patients with low baseline scores (<4) from the analysis (Figure 1). We continue to be most excited that rezpeg seems to have disease-modifying potential with sustained benefit after cessation of dosing (Figure 2).
Bank of America Securities
$0.60
Sell
-35.77%
Downside
Reiterated
09/13/23
Nektar Therapeutics (NKTR) Gets a Sell from Bank of America Securities
Goldman Sachs
$2.00
Sell
114.09%
Upside
Reiterated
04/17/23
Goldman Sachs Remains a Sell on Nektar Therapeutics (NKTR)
Best Analysts Covering Nektar Therapeutics
Which Analyst Should I Follow If I Want to Buy NKTR and Sell After:
1 Month
3 Months
1 Year
Success Rate
10/15 ratings generated profit
Average Return
+56.09%
initiated a sell rating 5 months ago
Copying Jessica Fye's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +56.09% per trade.
2 Years
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NKTR Analyst Recommendation Trends
Rating
Aug 23
Sep 23
Nov 23
Dec 23
Mar 24
Strong Buy
0
0
0
0
0
Buy
0
0
1
1
1
Hold
8
5
4
4
4
Sell
1
1
2
2
1
Strong Sell
0
0
0
0
0
total
9
6
7
7
6
Each month's total comprises the sum of three months' worth of ratings.
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
NKTR Financial Forecast
NKTR Stock Forecast FAQ
What is NKTR’s average 12-month price target, according to analysts?
Based on analyst ratings, Nektar Therapeutics’s 12-month average price target is $1.00.
What is NKTR’s upside potential, based on the analysts’ average price target?
Nektar Therapeutics has 7.04% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NKTR a Buy, Sell or Hold?
Nektar Therapeutics has a conensus rating of Hold which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.
What is Nektar Therapeutics’s price target?
The average price target for Nektar Therapeutics is $1.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $1.00 ,the lowest forecast is $1.00. The average price target represents 7.04% Increase from the current price of $0.934.
The highest analyst price target is $1.00 ,the lowest forecast is $1.00. The average price target represents 7.04% Increase from the current price of $0.934.
What do analysts say about Nektar Therapeutics?
Nektar Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.
How can I buy shares of NKTR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.